Please Wait.....
Report
Rare Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area (Hematologic Diseases, Cancer, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Endocrine Diseases, Musculoskeletal Diseases, Others), By Route of Administration (Injectable, Oral, Others), By Drug Type (Biologics, Biosimilar, Small Molecules), By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F
Market Report I 2025-06-13 I 185 Pages I TechSci Research
Market Overview
The Global Rare Disease Therapeutics Market was valued at USD 121.05 Billion in 2024 and is projected to reach USD 219.66 Billion by 2030, growing at a CAGR of 10.40%. This market focuses on treatments for rare or orphan diseases, which individually affect small populations but collectively impact millions worldwide. Despite their low prevalence, these diseases represent a significant healthcare concern due to limited treatment options and high unmet needs. The market's growth is driven by progress in genetic research, which has enabled the development of advanced therapies such as gene therapy and precision medicine. Regulatory incentives like the Orphan Drug Act in the U.S. and similar frameworks globally have encouraged pharmaceutical companies to invest in this sector. Additionally, increasing awareness through patient advocacy and healthcare organizations has elevated rare diseases as a priority, spurring funding and innovation. Together, these factors are fostering a supportive environment for therapeutic advancements and improving outcomes for individuals affected by rare diseases.
Key Market Drivers
Rising Number of Patients with Rare Diseases
The growing recognition of rare diseases, which number around 7,000 globally, is a significant driver for the market. Conditions such as cystic fibrosis, cat eye syndrome, and numerous rare cancers and metabolic disorders often lack effective treatments. According to the Indian Organization for Rare Diseases, a vast majority of these conditions still do not have targeted therapies. Similarly, the World Economic Forum reported in 2020 that approved treatments are available for only about 5% of known rare diseases, underscoring an enormous unmet medical need. In Europe, rare diseases affect approximately 6% to 8% of the population, amounting to nearly 30 million people. However, the individual rarity of each condition leads to limited research investment, late diagnoses, and inadequate treatment infrastructure. This "rarity paradox" highlights the mismatch between collective prevalence and resource allocation, emphasizing the need for policy reform, cross-border research collaboration, and incentivized innovation to address therapeutic gaps for this large patient population.
Key Market Challenges
Accurate Diagnosis
Accurate diagnosis remains a major barrier in rare disease management. For many patients, securing a definitive diagnosis can take up to five years due to the subtle and often non-specific nature of symptoms. Physicians may struggle to identify rare conditions, particularly those they have never encountered. In such cases, comprehensive genetic testing may be required to detect disease-related mutations. However, interpreting complex genetic data poses challenges, especially in the absence of specialists. To improve diagnostic accuracy, patients benefit most from referrals to clinical geneticists or healthcare providers with experience in managing rare diseases. Delays in diagnosis hinder timely treatment initiation and reduce eligibility for clinical trials, making early identification critical for improving patient outcomes and accelerating research.
Key Market Trends
Growing Product Innovation
The growing demand for rare disease treatments has spurred significant product innovation. Leading pharmaceutical companies are accelerating the development and global rollout of new therapies. For example, in February 2023, Sanofi announced plans to launch two orphan drugs in India: Nexviazyme (avalglucosidase alfa) for Pompe disease and Xenpozyme (olipudase alfa) for Niemann-Pick disease (ASMD). Both drugs are already approved in markets such as the U.S., EU, UK, Japan, and Australia, and have received waivers for Phase III and IV trials in India. This trend highlights a broader industry shift toward expanding access to specialized treatments in emerging markets, supported by regulatory flexibility and increased investment in research. As more therapies secure global approvals, innovation continues to reshape the landscape, offering hope for patients with previously untreatable conditions.
Key Market Players
- Novartis AG
- AstraZeneca PLC
- Pfizer Inc.
- Sanofi SA
- AbbVie Inc
- Bristol-Myers Squibb Co
- Bayer AG
- F Hoffmann-La Roche Ltd.
- Amgen Inc
- Eisai Co Ltd
- Novo Nordisk A/S
Report Scope:
In this report, the Global Rare Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Rare Disease Therapeutics Market, By Therapeutic Area:
o Hematologic Diseases
o Cancer
o Infectious Diseases
o Cardiovascular Diseases
o Metabolic Diseases
o Endocrine Diseases
o Musculoskeletal Diseases
o Others
- Rare Disease Therapeutics Market, By Route of Administration:
o Injectable
o Oral
o Others
- Rare Disease Therapeutics Market, By Drug Type:
o Biologics
o Biosimilar
o Small Molecules
- Rare Disease Therapeutics Market, By Distribution Channel:
o Specialty Pharmacies
o Hospital Pharmacies
o Online Pharmacies
- Rare Disease Therapeutics Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Rare Disease Therapeutics Market.
Available Customizations:
Global Rare Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Rare Disease Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Area (Hematologic Diseases, Cancer, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Endocrine Diseases, Musculoskeletal Diseases, Others)
5.2.2. By Route of Administration (Injectable, Oral, Others)
5.2.3. By Drug Type (Biologics, Biosimilar, Small Molecules)
5.2.4. By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Rare Disease Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Area
6.2.2. By Route of Administration
6.2.3. By Drug Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Rare Disease Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Area
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Rare Disease Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Area
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Rare Disease Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Area
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Distribution Channel
7. Europe Rare Disease Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutic Area
7.2.2. By Route of Administration
7.2.3. By Drug Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Rare Disease Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Area
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Distribution Channel
7.3.2. United Kingdom Rare Disease Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Area
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Distribution Channel
7.3.3. Italy Rare Disease Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Area
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Distribution Channel
7.3.4. France Rare Disease Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Area
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Rare Disease Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Area
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Distribution Channel
8. Asia-Pacific Rare Disease Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutic Area
8.2.2. By Route of Administration
8.2.3. By Drug Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Rare Disease Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Area
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Rare Disease Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Area
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Rare Disease Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Area
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Rare Disease Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Area
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Rare Disease Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Area
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Distribution Channel
9. South America Rare Disease Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Area
9.2.2. By Route of Administration
9.2.3. By Drug Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Rare Disease Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Area
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Distribution Channel
9.3.2. Argentina Rare Disease Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Area
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Distribution Channel
9.3.3. Colombia Rare Disease Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Area
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Distribution Channel
10. Middle East and Africa Rare Disease Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Area
10.2.2. By Route of Administration
10.2.3. By Drug Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Rare Disease Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Area
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Distribution Channel
10.3.2. Saudi Arabia Rare Disease Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Area
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Distribution Channel
10.3.3. UAE Rare Disease Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Area
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Rare Disease Therapeutics Market: SWOT Analysis
14. Competitive Landscape
14.1. Novartis AG
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. AstraZeneca PLC
14.3. Pfizer Inc.
14.4. Sanofi SA
14.5. AbbVie Inc
14.6. Bristol-Myers Squibb Co
14.7. Bayer AG
14.8. F Hoffmann-La Roche Ltd.
14.9. Amgen Inc
14.10.Eisai Co Ltd
14.11.Novo Nordisk A/S
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security